Cobolimab/Dostarlimab Combination Shows Initial Efficacy and Safety Signals in Advanced NSCLC
The anti-TIM3 monoclonal antibody, cobolimab utilized in combination with the anti-PD–1 antibody dostarlimab-gxly demonstrated promising signs of clinical activity and an acceptable safety profile across all dose levels in heavily pretreated patients with advanced/metastatic non–small cell lung cancer.
Source: onclive.com